Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.
Past Team (4)Update
Funding Rounds (2) - $32.5MUpdate
IT and Healthcare VC
Novo A/S is the holding company of the Novo Group, wholly-owned by the Novo Nordisk Foundation.
Bay City Capital LLC (Bay City Capital) was established in 1997 for the purpose of managing...
Premier angel investment group
400 Oyster Point Boulevard
South San Francisco, CA 94080